From molecule to medicine: the process behind patient-ready treatments
Z článku vyplývá, že Ian Fox pracuje na pomezí výzkumu a aplikace, kdy proměňuje slibné molekuly v real-world léčiva. Zdůrazňuje, že klíčové je zajistit opakovatelnost, kvalitu a bezpečnost výrobku, aby u každého pacienta byl stejný efekt a dávka. Rozhovor ukazuje jeho postup od výrobní komerční linky k vývoji farmaceutických produktů, zdůrazňuje potřebu dřívějšího hodnocení výrobních procesů a spolupráci v týmu, včetně využití budoucích nástrojů jako umělá inteligence k snižování rizik. Celé úsilí je postavené na koordinaci mezi vědou a klinickou praxí, aby se produkt dostal na trh a sloužil pacientům vždy se stejnou kvalitou.
“We need to make sure that it’s scalable, safe, and reproducible—so that every patient gets the same medicine every time.”
As a CMC lead focused on new asset development, Ian Fox works at the intersection of research and application—taking promising molecules and turning them into real-world treatments. He explains his work as “a kind of bridge between early research identification of a target area and making the end product a sustainable, controlled, safe, quality product that can meet a patient’s needs.”
Ian supports the push from medicinal chemistry into clinical development, translating discovery into consistent, high-quality products. That means evaluating manufacturing processes early, making sure they are viable not just in theory but in scale. “It has to be always the same quality, the same dose, the same perfect medicine every time,” he says.
Ian did not begin in development. His journey started in commercial manufacturing, then he saw an opportunity to move closer to impact. “The move into pharmaceutical development gives me the opportunity to reach more patients and change their lives.”
That shift required growth. He “climbed the ladder” and completed a master’s focused on innovative manufacturing. Ipsen’s structure allowed him to move across teams, expand his technical scope, and step into a role where science connects directly to patients.
He believes the future lies in better tools and deeper collaboration. “With advancements in AI, we might reduce the risk or the level of testing we have to execute—through more effective modeling,” he says. “Tools like this will aid scientists and let us focus more on the work itself.”
In the end, for Ian, everything comes together through collaboration. “If we can’t collaborate, the product doesn’t make it to market. By working together, we work towards delivering the same results for every patient every time.”
Ipsen
Ukázka dat Dun & Bradstreet
| Název společnosti | AUDI Aktiengesellschaft |
|---|---|
| D-U-N-S číslo | 315731679 |
| Registrační číslo / Popis | HRB1 Register Number (DE) |
| Registrační číslo / Popis | 85049B1 Derived Unique Register Number (DE) |
| Registrační číslo / Popis | DE811115368 Value Added Tax Number (DE) |
| Telefon | +49 841890 |
| Typ subjektu | Corporation |
| Právní forma | Deemed Public Limited Company |
| Roční obrat | 64 500 000 000 EUR / 71 157 238 500 USD - 01.01.2024 |
| Počet zaměstnanců | 86 900 - 01.01.2024 |
| Stav | Active |
| Adresa | Auto-Union-Str. 1, Ingolstadt, 85057, Germany |
| Webová stránka | www.audi.com |
| [email protected] | |
| Předmět podnikání | Mfg motor vehicle/car bodies |
| Typ vlastnictví | Privately owned |
| Datum založení | 16.04.1884 |
| Statutární zástupci | Gernot Döllner |
| Vlastníci | Bundesland Niedersachsen, Streubesitz, GOVERNMENT OF QATAR, Ferdinand Porsche Familien-Privatstiftung, Kai Alexander Porsche, Peter Daniell Porsche, Ferdinand Oliver Porsche, Geraldine Porsche, Mark Philipp Porsche, Hubertus Josef Kiesling, Diana Porsche, Andreas Kiesling, Peter Daniell Porsche, Kai Alexander Porsche, Ferdinand Oliver Porsche, Mark Philipp Porsche, Geraldine Porsche, Diana Porsche, Hubertus Josef Kiesling, Andreas Kiesling, Wolfgang Porsche, Stephanie Porsche- Schröder, Felix Alexander Porsche, Christian Porsche, Ferdinand Rudolf Wolfgang Porsche |
